Results 121 to 130 of about 1,279,543 (154)

Hypothalamic obesity in pediatric vs. adult craniopharyngioma: mechanisms, management, and cardiometabolic outcomes. [PDF]

Pituitary
Gupta K, Zeinali M, Altschul D, Agarwal V, Karsy M.   +4 more
europepmc   +1 more source

GLP-1 receptor agonists in type 1 diabetes: expanding the therapeutic landscape beyond insulin. [PDF]

Lancet Reg Health Eur
Dimitriadis GD, Lambadiari V.
europepmc   +1 more source

Not only gut feelings: pancreatic hormone, amylin, controls emotionality and sociability, in a sex divergent manner. [PDF]

Transl Psychiatry
Byun S, Sotzen MR, Knappenberger MA, Olekanma DI, Bento M, Skibicka KP.   +5 more
europepmc   +1 more source

Anti-Obesity Drugs: The Rising Significance of GLP-1Agonist, Tirzepatide. [PDF]

J Midlife Health
Agrawal PK, Garg R.
europepmc   +1 more source

Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden. [PDF]

Toxicol Rep
Dugbartey GJ, Alornyo KK, Dapaa-Addo CO, Kwashie EK, Harley Y, Asiedu BN.   +5 more
europepmc   +1 more source

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. [PDF]

Diabetes Obes Metab
Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, Qu H, Briere DA, Haupt A, Mather KJ, Pratt E.   +8 more
europepmc   +1 more source

Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism. [PDF]

Nat Metab
Lewis JE, Montaner M, Nuzzaci D, James-Okoro PP, Harada N, Inagaki N, Dodson WS, Knerr PJ, Douros JD, Gribble FM, Reimann F.   +10 more
europepmc   +1 more source

Incretin polyagonists as an alternative to bariatric surgery to manage obesity. [PDF]

World J Gastrointest Pathophysiol
Manoj RJ, Fernandez CJ, Nair S, Pappachan JM.   +3 more
europepmc   +1 more source

Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review. [PDF]

Curr Obes Rep
Tzeravini E, Simati S, Anastasiou IA, Dalamaga M, Kokkinos A.   +4 more
europepmc   +1 more source

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. [PDF]

Mol Metab
Briere DA, Qu H, Lansu K, He MM, Moyers JS, Coskun T, Long A, Allen D, O'Farrell L, Bowen B, Pratt E, Tidemann-Miller B, Tham LS, Ibriga H, Alsina-Fernandez J, Mather KJ, Haupt A, Bhattachar SN.   +17 more
europepmc   +1 more source